Heron Therapeutics, Inc.
HRTX
$1.36
-$0.05-3.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 98.07% | 90.38% | 87.72% | 76.64% | 64.77% |
| Total Depreciation and Amortization | -16.16% | -17.98% | -14.04% | -11.73% | -6.16% |
| Total Amortization of Deferred Charges | 110.38% | 141.12% | 183.48% | 264.60% | 153.66% |
| Total Other Non-Cash Items | -51.83% | -46.38% | -52.11% | -54.89% | -51.39% |
| Change in Net Operating Assets | -1,286.16% | -542.49% | -264.40% | 95.74% | 109.62% |
| Cash from Operations | -35.04% | 49.58% | 61.68% | 91.60% | 83.54% |
| Capital Expenditure | 17.50% | -37.40% | -10.42% | 22.88% | -74.82% |
| Sale of Property, Plant, and Equipment | 515.38% | 430.77% | 107.69% | 333.33% | -92.40% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 197.18% | 232.01% | 4.43% | -100.77% | -260.94% |
| Cash from Investing | 187.00% | 212.23% | 4.00% | -105.34% | -279.28% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.60% | -98.00% | -98.00% | -98.75% | -60.62% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1,333.33% | 155.70% | 136.32% | 129.21% | 101.75% |
| Cash from Financing | -97.65% | -98.17% | -98.26% | -98.68% | -27.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -137.98% | 82.21% | -121.60% | 41.47% | 114.01% |